文献速递冠心病血脂与心血管预防

抑制S-腺苷同型半胱氨酸水解酶通过表观遗传上调p66shc氧化应激通路诱导内皮功能障碍

Inhibition of S-Adenosylhomocysteine Hydrolase Induces Endothelial Dysfunction via Epigenetic Regulation of p66shc-Mediated Oxidative Stress Pathway.
PubMed 文献 · Circulation · 2019-01-01

该研究在apoE-/-小鼠中通过药物抑制、shRNA敲低及SAHH+/-基因敲除升高血浆SAH水平,发现SAHH抑制损害内皮依赖性血管舒张并降低一氧化氮生物利用度,机制涉及p66shc启动子低甲基化上调p66shc表达和活性氧生成;在冠心病患者与健康对照中,血浆SAH水平与血流介导舒张呈负相关、与氧化应激正相关。

要点

  • 升高血浆SAH可损害内皮依赖性血管舒张并降低一氧化氮生物利用度。
  • SAHH抑制通过p66shc启动子低甲基化上调p66shc表达,增加活性氧生成。
  • 抗氧化剂或p66shc siRNA可减轻SAHH抑制所致的内皮功能障碍。

核心结论

  • 抑制SAHH导致血浆SAH水平升高,并通过表观遗传上调p66shc介导的氧化应激通路诱导内皮功能障碍。

研究设计与样本

  • 研究在apoE-/-小鼠中采用腺苷二醛饮食补充、静脉注射表达SAHH shRNA的逆转录病毒及SAHH+/-杂合敲除三种方式升高血浆SAH,并检测主动脉内皮功能。
  • 在冠心病患者和健康对照中分析血浆SAH水平与内皮功能障碍的关系。

主要发现

  • SAHH+/-小鼠及经腺苷二醛或SAHH shRNA处理的apoE-/-小鼠血浆SAH水平升高。
  • SAHH抑制的小鼠在乙酰胆碱处理后内皮依赖性血管舒张受损、一氧化氮生物利用度降低,该效应被NG-硝基-L-精氨酸甲酯完全消除。
  • SAHH抑制诱导小鼠主动脉和人主动脉内皮细胞中活性氧产生及p66shc表达。
  • 抗氧化剂和p66shc siRNA可阻止SAHH抑制诱导的活性氧生成,并减轻高SAH小鼠受损的内皮血管舒缩反应。
  • SAHH抑制引起p66shc基因启动子低甲基化并抑制DNA甲基转移酶1表达,过表达DNA甲基转移酶1可消除SAHH抑制诱导的p66shc上调。

关键数值与推荐

  • SAHH+/-小鼠及经腺苷二醛或SAHH shRNA处理的apoE-/-小鼠血浆SAH水平升高。
  • 内皮依赖性血管舒张在乙酰胆碱处理后受损,该效应被NG-硝基-L-精氨酸甲酯完全消除。
  • p66shc siRNA和抗氧化剂可阻止SAHH抑制诱导的活性氧生成并减轻内皮血管舒缩反应受损。

临床怎么用

  • 血浆SAH水平可能作为内皮功能障碍和动脉粥样硬化风险的生物标志物。
  • 靶向SAHH-p66shc-氧化应激通路可能为改善内皮功能提供潜在干预方向。

局限性

  • 研究未报告样本量、具体P值及效应量等定量数据。
  • SAH与内皮功能障碍的因果关系及临床干预价值仍需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Elevated levels of S-adenosylhomocysteine (SAH), the precursor of homocysteine, are positively associated with the risk of cardiovascular disease and with the development and progression of atherosclerosis. However, the role of SAH in endothelial dysfunction is unclear. METHODS: Apolipoprotein E-deficient ( apoE-/-) mice received dietary supplementation with the SAH hydrolase (SAHH) inhibitor adenosine dialdehyde or were intravenously injected with a retrovirus expressing SAHH shRNA. These 2 approaches, along with the heterozygous SAHH gene knockout ( SAHH+/-) mouse model, were used to elevate plasma SAH levels and to examine the role of SAH in aortic endothelial dysfunction. The relationship between plasma SAH levels and endothelial dysfunction was also investigated in human patients with coronary artery disease and healthy control subjects. RESULTS: Plasma SAH levels were increased in SAHH+/- mice and in apoE-/- mice after dietary administration of adenosine dialdehyde or intravenous injection with SAHH shRNA. SAHH+/- mice or apoE-/- mice with SAHH inhibition showed impaired endothelium-dependent vascular relaxation and decreased nitric oxide bioavailability after treatment with acetylcholine; this was completely abolished by the administration of the endothelial nitric oxide synthase inhibitor NG-nitro-l-arginine methyl ester. Furthermore, SAHH inhibition induced production of reactive oxygen species and p66shc expression in the mouse aorta and human aortic endothelial cells. Antioxidants and p66shc siRNA prevented SAHH inhibition-induced generation of reactive oxygen species and attenuated the impaired endothelial vasomotor responses in high-SAH mice. Moreover, inhibition of SAHH induced hypomethylation in the p66shc gene promoter and inhibited expression of DNA methyltransferase 1. Overexpression of DNA methyltransferase 1, induced by transduction of an adenovirus, was sufficient to abrogate SAHH inhibition-induced upregulation of p66shc expression. Finally, plasma SAH levels were inversely associated with flow-mediated dilation and hypomethylation of the p66shc gene promoter and positively associated with oxidative stress levels in patients with coronary artery disease and healthy control subjects. CONCLUSIONS: Our findings indicate that inhibition of SAHH results in elevated plasma SAH levels and induces endothelial dysfunction via epigenetic upregulation of the p66shc-mediated oxidative stress pathway. Our study provides novel molecular insight into mechanisms of SAH-associated endothelial injury that may contribute to the development of atherosclerosis. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT03345927.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Xiao Y, Xia J, Cheng J, et al. Inhibition of S-Adenosylhomocysteine Hydrolase Induces Endothelial Dysfunction via Epigenetic Regulation of p66shc-Mediated Oxidative Stress Pathway. Circulation. 2019. PMID: 30773021. doi:10.1161/CIRCULATIONAHA.118.036336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。